Curated By Isabella Tang
Shein's stock has seen a significant decline following an urgent recall of a contact-lens cleaner in Australia and New Zealand. The recall raises concerns about product safety and the impact on the fast-fashion giant's reputation.
Hong Kong shares showed slight gains today as investors reacted to mixed signals from the global market, particularly in the tech sector. The resilience of local stocks comes despite ongoing concerns regarding artificial intelligence developments and their impact on the broader economy.
Forms Syntron, a leading technology firm, has successfully launched its initial public offering in Hong Kong, raising HK$940 million. This move is seen as a significant step in attracting the next generation of entrepreneurs and investors in the region.
Hong Kong is set to invest $28.6 billion in a transformative project aimed at developing new homes, logistics hubs, and a technology city. This initiative will reshape the landscape of the New Territories, addressing housing shortages and promoting economic growth.
Hong Kong's retail sector is witnessing a gradual recovery as malls introduce new stores and events to attract customers. Hang Lung Properties' CEO highlights the positive changes and strategies implemented to revitalize the shopping experience.
A recent report highlights how a non-resident Indian couple navigates the financial landscape of Hong Kong, where low taxes help offset the high cost of living. Their experience sheds light on the unique lifestyle opportunities available in this vibrant city.
Eleven oncologists from Keralam are gearing up to attend the prestigious World Cancer Congress, aiming to share insights and advancements in cancer treatment. This international event will provide a platform for knowledge exchange and collaboration among global experts in oncology.
Consensus, a leading blockchain technology conference, is set to return to Hong Kong for its third consecutive year, this time with an enhanced emphasis on artificial intelligence. The event aims to bridge the gap between blockchain and AI, showcasing innovations that could reshape various industries.
Antengene has published a groundbreaking preclinical research paper highlighting the efficacy of its CD73 small molecule inhibitor ATG-037 in combination with Selinexor for cancer gene therapy. This innovative approach could significantly enhance treatment options for various cancer types.
Firmus, a prominent player in the biotechnology sector, is reportedly planning to raise up to $5 billion through an initial public offering (IPO) in Australia. This move comes as the company seeks to capitalize on increasing investor interest and expand its operations.
Hong Kong's financial sector faces increasing calls to reevaluate its trading hours after South Korea's recent changes. Industry experts argue that adapting to global standards is essential for maintaining competitiveness.
As tariffs reshape global trade dynamics, several companies that previously left China are now reconsidering their positions and returning. This shift highlights the complexities of international business strategies in a changing economic environment.
Recent research suggests that common osteoporosis medications may have a protective effect against dementia. The study, which analyzed data from 120,000 adults, highlights a potential new avenue for dementia prevention strategies.
The upcoming Chinese defence forum is poised to address escalating tensions in the Asia-Pacific region. With key stakeholders in attendance, the event will focus on security collaboration and military strategies.
Hong Kong's cybersecurity agency warns residents about a surge in phishing activities that lead to unauthorized credit card transactions. The alert highlights the importance of vigilance and protective measures against potential scams.
In a vibrant display of creativity and community spirit, local artists and residents have come together to produce a monumental artwork for the Hong Kong Trade Development Council's 60th anniversary. This collaborative effort not only highlights the rich cultural tapestry of Hong Kong but also symbolizes resilience and unity in the face of challenges.
Zhipu AI has successfully returned to the Hong Kong equity market following a lockup period, raising an impressive $4 billion through a significant placement. This move marks a pivotal moment for the company as it aims to bolster its growth and innovation in the AI sector.
Z.ai has successfully raised $5 billion in funding in Hong Kong, marking a significant milestone for the artificial intelligence sector. The funding includes an impressive $3 billion in zero-interest bonds, showcasing investor confidence in the company's future.
Recent findings from the HARMONi-2 trial reveal that Ivonescimab significantly improves overall survival rates in patients with PD-L1-positive non-small cell lung cancer. The results were presented at the World Conference on Lung Cancer 2026, highlighting a potential new standard of care in oncology.
China's leading artificial intelligence company, Z.AI, has successfully raised $5 billion through new share and convertible bond sales. This funding will significantly bolster its research and development efforts in the rapidly evolving AI sector.
Hong Kong has launched its first five-year plan aimed at revitalizing its economy and enhancing its global competitiveness. The plan outlines strategic initiatives to foster innovation, bolster infrastructure, and attract talent in the face of ongoing challenges.
The once-thriving retail empires of Hong Kong are facing unprecedented challenges as plunging rents and crippling debt bring them to their knees. This report delves into the factors contributing to the decline of these 'shop kings' and the future of retail in the region.
Z.AI, a leading Chinese artificial intelligence company, has successfully raised $5 billion through a combination of new share and convertible bond sales. This significant capital influx is poised to bolster the company's expansion and innovation efforts in the rapidly evolving AI sector.
A groundbreaking study presented at the World Conference on Lung Cancer 2026 reveals that Ivonescimab significantly improves overall survival rates in patients with PD-L1-positive non-small cell lung cancer compared to Pembrolizumab. This advancement could reshape first-line treatment protocols for NSCLC globally.
